Kastrukoff L F, Oger J J, Tourtellotte W W, Sacks S L, Berkowitz J, Paty D W
Division of Neurology, University of British Columbia, Vancouver, Canada.
Neurology. 1991 Dec;41(12):1936-41. doi: 10.1212/wnl.41.12.1936.
Immunologic functions are studied in conjunction with a placebo-controlled trial of lymphoblastoid interferon (IFN) in patients with chronic progressive (CP) multiple sclerosis. Prior to treatment, CD4+ cells are significantly increased and CD8+ cells decreased in the blood of MS patients. Both CD5+ and CD4+ cells increase significantly with IFN therapy early during the treatment phase of the trial, while the number of CD8+ cells decreases steadily, becoming significant at 6 months. CNS IgG synthesis rates increase with IFN treatment and maximize at 3 months. Serum antiviral activity also increases with IFN treatment. In the IFN-treated group, a trend toward improvement, determined clinically and by MRI, likely reflects the influence of a subpopulation of 10 patients. This subpopulation is now further characterized by an early increase in CNS IgG synthesis and numbers of CD5+ cells in the blood. Although these immune functions may identify a number of CP MS patients who might benefit from IFN, it is unlikely that these mechanisms actually mediate the potentially beneficial effects of this cytokine.
在一项针对慢性进展型（CP）多发性硬化症患者的淋巴母细胞干扰素（IFN）安慰剂对照试验中，对免疫功能进行了研究。治疗前，MS患者血液中的CD4+细胞显著增加，CD8+细胞减少。在试验治疗阶段早期，IFN治疗后CD5+和CD4+细胞均显著增加，而CD8+细胞数量稳步下降，在6个月时变得显著。CNS IgG合成率随IFN治疗而增加，并在3个月时达到最大值。血清抗病毒活性也随IFN治疗而增加。在IFN治疗组中，通过临床和MRI确定的改善趋势可能反映了10名患者亚群的影响。该亚群现在的进一步特征是CNS IgG合成早期增加以及血液中CD5+细胞数量增加。尽管这些免疫功能可能识别出一些可能从IFN中受益的CP MS患者，但这些机制不太可能实际介导这种细胞因子的潜在有益作用。
